A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Zydus Cadila receives US FDA approval for anti-inflammatory drug budesonide

Budesonide is estimated to have annual sales of $ 285.8 million, according to IMS

BS B2B Bureau  |  Ahmedabad 

The Ahmedabad-based Zydus Cadila has received the final approval from the US Food & Drug Administration (FDA) to market budesonide capsules, 3 mg (enteric coated). The drug is a corticosteroid used for its anti-inflammatory action.

Zydus Cadila will produce the approved drug at the group's formulation manufacturing facility at the Pharma SEZ in Ahmedabad. The estimated sales of budesonide is $ 285.8 million (IMS MAT March 2017).

The group now has more than 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila receives US FDA approval for anti-inflammatory drug budesonide

Budesonide is estimated to have annual sales of $ 285.8 million, according to IMS

Budesonide is estimated to have annual sales of $ 285.8 million, according to IMS
The Ahmedabad-based Zydus Cadila has received the final approval from the US Food & Drug Administration (FDA) to market budesonide capsules, 3 mg (enteric coated). The drug is a corticosteroid used for its anti-inflammatory action.

Zydus Cadila will produce the approved drug at the group's formulation manufacturing facility at the Pharma SEZ in Ahmedabad. The estimated sales of budesonide is $ 285.8 million (IMS MAT March 2017).

The group now has more than 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

 image
Business Standard
177 22